ArticleJournal of clinical microbiology2006
Candidemia in Norway (1991 to 2003): results from a nationwide study.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- High burden of Candida blankii (syn.Tardiomyces blankii) bloodstream infections among neonates in an intensive care unit in Bangladesh.BMC infectious diseases · 2026Article
- Antifungal Resistance Surveillance: Insights From National Mycology Reference Centers and Expert Mycology Laboratories.Open forum infectious diseases · 2026Article
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Article
- Case report:Medical mycology case reports · 2024Article
- The yeast genus Tardiomyces gen. nov. with one new species and two new combinations.Infection · 2024Article
- Prevalence and Species Distribution ofJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Continuing Shifts in Epidemiology and Antifungal Susceptibility Highlight the Need for Improved Disease Management of Invasive Candidiasis.Microorganisms · 2022Review
- Update 2016-2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective.Journal of fungi (Basel, Switzerland) · 2021Article
- Molecular Methods for the Diagnosis of Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2020Review
- Resistance rates of non-Infection and drug resistance · 2019Article
- Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives.Frontiers in pediatrics · 2019Review
- Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.Journal of clinical microbiology · 2018Article
- Estimating the Burden of Serious Fungal Infections in Uruguay.Journal of fungi (Basel, Switzerland) · 2018Article
- An Estimate of the Burden of Fungal Disease in Norway.Journal of fungi (Basel, Switzerland) · 2018Article
- Burden of bloodstream infection in an area of Mid-Norway 2002-2013: a prospective population-based observational study.BMC infectious diseases · 2017Observational
- Comparison of BACTEC™ blood culture media for the detection of fungemia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Article
- Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system.Scientific reports · 2016Article
- Invasive Esophageal Candidiasis with Chronic Mediastinal Abscess and Fatal Pneumomediastinum.The American journal of case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A long-term, nationwide prospective candidemia study has been ongoing in Norway since 1991. All medical microbiological laboratories in the country have participated. During the period 1991 to 2003 a total of 1,393 episodes of candidemia occurred in 1,348 patients. The incidence of candidemia episodes per 100,000 inhabitants increased from approximately 2 episodes in the early 1990s to 3 episodes in 2001 to 2003. The average annual incidences varied markedly between the age groups. The incidence was high in patients aged < 1 year and in patients aged > or = 70 years. In patients > or = 80 years of age, the incidence has increased during the last 3 years from an annual average of 6.5 to 15.6 cases/100,000 inhabitants in 2003. Four Candida species (C. albicans [70%], C. glabrata [13%], C. tropicalis [7%], and C. parapsilosis [6%]) accounted for 95.5% of the isolates. The species distribution has been constant during the 13-year study period. The distribution of the most important species varied with the age of the patient. In patients < 1 year of age, the majority of episodes were caused by C. albicans (91%). The occurrence of C. glabrata increased with age. In patients > or = 80 years of age, approximately 1/3 of all episodes were due to this species. All C. albicans strains were susceptible to fluconazole. The percentage of yeast isolates with decreased susceptibility to fluconazole (MICs > or = 16 microg/ml) was 10.7% during the first period of this study (1991 to 1996) and 11.7% during the second period (1997 to 2003).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.